Drosophila Models of Alzheimer's Disease: Advances, Limits, and Perspectives
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Amyloid-β protein precursor (AβPP) and the microtubule-associated protein tau (MAPT) are the two key players involved in Alzheimer's disease (AD) and are associated with amyloid plaques and neurofibrillary tangles respectively, two key hallmarks of the disease. Besides vertebrate models, Drosophila models have been widely used to understand the complex events leading to AD in relation to aging. Drosophila benefits from the low redundancy of the genome which greatly simplifies the analysis of single gene disruption, sophisticated molecular genetic tools, and reduced cost compared to mammals. The aim of this review is to describe the recent advances in modeling AD using fly and to emphasize some limits of these models. Genetic studies in Drosophila have revealed some key aspects of the normal function of Appl and Tau, the fly homologues of AβPP and MAPT that may be disrupted during AD. Drosophila models have also been useful to uncover or validate several pathological pathways or susceptibility genes, and have been readily implemented in drug screening pipelines. We discuss some limitations of the current models that may arise from differences in structure of Appl and Tau compared to their human counterparts or from missing AβPP or MAPT protein interactors in flies. The advent of new genome modification technologies should allow the development of more realistic fly models and to better understand the relationship between AD and aging, taking advantage of the fly's short lifespan.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The global prevalence of dementia: a systematic review and metaanalysis.
Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., & Ferri, C. P. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.007 · Cited by 4,941 · cited 1×
“worldwide potential impact in terms of public health 27 and economic burden in our aging societies [1].”
BackgroundAmyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · cited 1×
“These initial advances led Hardy and colleagues to propose the amyloid cascade hypothesis [3, 4].”
Karran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188 · cited 1×
“These failures do not fully rule out the amyloid cascade hypothesis [7], since most of the trials have been performed on patients with mild or advanced stages of the disease.”
Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models
Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744 · cited 1×
“However, until now, all these trials failed to delay the disease [6].”
Tau pathology and neurodegeneration
Spillantini, M. G., & Goedert, M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70090-5 · Cited by 1,133
Tau phosphorylation: the therapeutic challenge for neurodegenerative disease
Hanger, D. P., Anderton, B. H., & Noble, W. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.01.003 · Cited by 965 · cited 3×
“context dependent manner [71].”
InfluentialTauopathy in Drosophila : Neurodegeneration Without Neurofibrillary Tangles
Wittmann, C. W., Wszolek, M. F., Shulman, J. M., Salvaterra, P. M., Lewis, J., Hutton, M., & Feany, M. B. (2001) · Science · doi:10.1126/science.1062382 · Cited by 939
The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives
Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.010 · Cited by 786 · cited 1×
“Nevertheless, these therapeutic failures boosted the development of alternative theoretical frameworks to describe AD [8–11].”
The acetylation of tau inhibits its function and promotes pathological tau aggregation
Cohen, T. J., Guo, J. L., Hurtado, D. E., Kwong, L. K., Mills, I. P., Trojanowski, J. Q., & Lee, V. M. Y. (2011) · Nature Communications · doi:10.1038/ncomms1255 · Cited by 724 · cited 1×
“lation, regulation of microtubule binding, and various 626 tauopathies [89] are conserved in Tau.”
BackgroundPhysiological release of endogenous tau is stimulated by neuronal activity
Pooler, A. M., Phillips, E. C., Lau, D. H. W., Noble, W., & Hanger, D. P. (2013) · The EMBO Reports · doi:10.1038/embor.2013.15 · Cited by 642 · cited 1×
“Finally, MAPT is released at 558 the synapse, suggesting that it may have a new role 559 in neuronal signaling [84].”
BackgroundTau promotes neurodegeneration through global chromatin relaxation
Frost, B., Hemberg, M., Lewis, J., & Feany, M. B. (2014) · Nature Neuroscience · doi:10.1038/nn.3639 · Cited by 495 · cited 3×
“[139].”
Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo
Fulga, T. A., Elson-Schwab, I., Khurana, V., Steinhilb, M. L., Spires, T. L., Hyman, B. T., & Feany, M. B. (2007) · Nature Cell Biology · doi:10.1038/ncb1528 · Cited by 452 · cited 2×
“Interestingly several cytoskeleton proteins, including Actin, are modulators of Tau toxicity and some of them co-localize with fibrillar Tau in AD brains [106, 127, 129].”
Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology
GERAD consortium, Chapuis, J., Hansmannel, F., Gistelinck, M., Mounier, A., Van Cauwenberghe, C., Kolen, K. V., Geller, F., Sottejeau, Y., Harold, D., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.1 · Cited by 407
Tau Promotes Neurodegeneration via DRP1 Mislocalization In Vivo
DuBoff, B., Götz, J., & Feany, M. B. (2012) · Neuron · doi:10.1016/j.neuron.2012.06.026 · Cited by 377
Oxidative stress mediates tau-induced neurodegeneration in Drosophila
Dias-Santagata, D., Fulga, T. A., Duttaroy, A., & Feany, M. B. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28769 · Cited by 318 · cited 1×
“Furthermore, it was inferred from genetic manipulation of antioxidant defense mechanisms that these events could be triggered by increase in oxidative stress [139, 141] that can be generated in several ways in AD models.”
Genetic modifiers of tauopathy in Drosophila
Shulman, J. M., & Feany, M. B. (2003) · Genetics · doi:10.1093/genetics/165.3.1233 · Cited by 275
Frandemiche, M. L., De Seranno, S., Rush, T., Borel, E., Elie, A., Arnal, I., Lanté, F., & Buisson, A. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.4261-13.2014 · Cited by 272 · cited 1×
“key proteins, in a synaptic activity dependent man555 ner [80, 82].”
BackgroundTOR-Mediated Cell-Cycle Activation Causes Neurodegeneration in a Drosophila Tauopathy Model
Khurana, V., Lu, Y., Steinhilb, M. L., Oldham, S., Shulman, J. M., & Feany, M. B. (2006) · Current Biology · doi:10.1016/j.cub.2005.12.042 · Cited by 266 · cited 4×
“Importantly, in several studies, functional res1079 cue of MAPT or A 42 induced phenotypes could be 1080 observed after genetic manipulation of several genes 1081 involved in DNA repair, cell cycle, or chromatin relax1082 ation pathways (Chk2, p53, Rbf, dap/p27, Ago3), 1083 suggesting that nuclear events are an import…”
BackgroundInfluentialViolet, M., Delattre, L., Tardivel, M., Sultan, A., Chauderlier, A., Caillierez, R., Talahari, S., Nesslany, F., Lefebvre, B., Bonnefoy, E., et al. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00084 · Cited by 251
Maas, T., Eidenmüller, J., & Brandt, R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000389200 · Cited by 226
Eckert, A., Schmitt, K., & Götz, J. (2011) · Alzheimer's Research & Therapy · doi:10.1186/alzrt74 · Cited by 177
Sofola, O., Kerr, F., Rogers, I., Killick, R., Augustin, H., Gandy, C., Allen, M. J., Hardy, J., Lovestone, S., & Partridge, L. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1001087 · Cited by 174 · cited 1×
“of A 42 peptide [156].”
Shulman, J. M., Imboywa, S., Giagtzoglou, N., Powers, M. P., Hu, Y., Devenport, D., Chipendo, P., Chibnik, L. B., Diamond, A., Perrimon, N., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt478 · Cited by 167
Iijima-Ando, K., Sekiya, M., Maruko-Otake, A., Ohtake, Y., Suzuki, E., Lu, B., & Iijima, K. M. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002918 · Cited by 142
The proline-rich domain of tau plays a role in interactions with actin
He, H. J., Wang, X. S., Pan, R., Wang, D. L., Liu, M. N., & He, R. Q. (2009) · BMC Cell Biology · doi:10.1186/1471-2121-10-81 · Cited by 142
Petersen, A. J., Rimkus, S. A., & Wassarman, D. A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110470109 · Cited by 139 · cited 1×
“Interestingly, 1211 a recent study in another fly disease model, ataxia 1212 telangesia, suggests that activation of inflammatory 1213 pathways in glial cells could induce non autonomous 1214 neuronal death [151].”
BackgroundAmbegaokar, S. S., & Jackson, G. R. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr432 · Cited by 113 · cited 2×
“It has been instrumental to695 confirm the in vivo relevance of several Tau kinases696 and their associated residues such as GS3K [94],697 Par-1/MARK (at S262/S356) [95], CamK1 and698 Mekk1 [96].”
BackgroundCytoskeleton proteins are modulators of mutant tau-induced neurodegeneration in Drosophila
Blard, O., Feuillette, S., Bou, J., Chaumette, B., Frébourg, T., Campion, D., & Lecourtois, M. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm011 · Cited by 110 · cited 2×
“Interestingly several cytoskeleton proteins, including Actin, are modulators of Tau toxicity and some of them co-localize with fibrillar Tau in AD brains [106, 127, 129].”
MAP2c, but Not Tau, Binds and Bundles F-Actin via Its Microtubule Binding Domain
Roger, B., Al-Bassam, J., Dehmelt, L., Milligan, R. A., & Halpain, S. (2004) · Current Biology · doi:10.1016/j.cub.2004.01.058 · Cited by 110
S/P and T/P phosphorylation is critical for tau neurotoxicity in Drosophila
Steinhilb, M. L., Dias‐Santagata, D., Mulkearns, E. E., Shulman, J. M., Biernat, J., Mandelkow, E., & Feany, M. B. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21232 · Cited by 107 · cited 1×
“mutant (TauAP) does not disrupt the eye structure [98].”
Iijima, K., Gatt, A., & Iijima-Ando, K. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq200 · Cited by 96
Azorsa, D. O., Robeson, R. H., Frost, D., hoovet, B. M., Brautigam, G. R., Dickey, C., Beaudry, C., Basu, G. D., Holz, D. R., Hernandez, J. A., et al. (2010) · BMC Genomics · doi:10.1186/1471-2164-11-25 · Cited by 88 · cited 1×
“We recently used this paradigm to 699 analyze in vivo the role of additional putative MAPT 700 kinases identified in a systematic RNAi screen in 701 human cells [97] and found that the inactivation of 702 six of them (Argk/CKB, polo/PLK2, mnb/DYRK1A, 703 par1/MARK2, Drak/STK17B, CkI /CSNK1A1) 704 worsens the eye pheno…”
MethodFolwell, J., Cowan, C. M., Ubhi, K. K., Shiabh, H., Newman, T. A., Shepherd, D., & Mudher, A. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.014 · Cited by 83
Feuillette, S., Miguel, L., Frébourg, T., Campion, D., & Lecourtois, M. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06663.x · Cited by 81
Iijima-Ando, K., Zhao, L., Gatt, A., Shenton, C., & Iijima, K. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq068 · Cited by 72
Cited by
The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade
Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179941 · Cited by 870
Alzheimer's disease: experimental models and reality
Drummond, E., & Wisniewski, T. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1662-x · Cited by 810
“Other models have included invertebrate animals such as Drosophila melanogaster and Caenorhabditis elegans, as well as vertebrates such as zebrafish; however, given these models’ greater distance from human physiology they are less extensively used [13, 53, 104].”
BackgroundThe multiplex model of the genetics of Alzheimer's disease
Sims, R., Hill, M., & Williams, J. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0599-5 · Cited by 466
Tau physiology and pathomechanisms in frontotemporal lobar degeneration
Bodea, L., Eckert, A., Ittner, L. M., Piguet, O., & Götz, J. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13600 · Cited by 104
“Two other isoforms are characterized by alterations in the C-terminal region, whereas yet another isoform was found to be entirely absent from adult females (Bouleau and Tricoire 2015).”
BackgroundGenetically modified large animal models for investigating neurodegenerative diseases
Yang, W., Chen, X., Li, S., & Li, X.-J. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00729-8 · Cited by 45
Metadata
- Authors
- Bouleau, S., & Tricoire, H.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2015-04-13
- Volume
- 45
- Issue
- 4
- Pages
- 1015-1038
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1595377383
- Cited by
- 69
- References
- 36
- FWCI
- 5.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.